These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24741906)

  • 21. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
    Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
    Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
    Chu M; Cho SM; Choe BH; Cho MH; Kwon S; Lee WK
    J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):648-52. PubMed ID: 22688509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
    Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E
    Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
    Kim YJ; Paik SW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1454-60. PubMed ID: 22168753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic hepatitis B--treatment with nucleoside analogues.
    Leung N
    Med J Malaysia; 2005 Jul; 60 Suppl B():22-7. PubMed ID: 16108169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles.
    You H; Ma H; Liu T; Cong M; Wang P; Ou X; Wang X; Ren J; Li H; Wang B; Jia J
    J Viral Hepat; 2009 Dec; 16(12):876-82. PubMed ID: 19635048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
    Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
    Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
    Elefsiniotis I; Buti M; Jardi R; Vezali E; Esteban R
    Eur J Intern Med; 2009 Sep; 20(5):478-81. PubMed ID: 19712848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Rapti I; Dimou E; Mitsoula P; Hadziyannis SJ
    Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
    Wang JC; He LL; Chen Q
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients].
    Lin Q; Zhang DZ; Zhou Z; Hu P; Wang ZY; Shi XF; Zeng WQ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2010 May; 18(5):338-41. PubMed ID: 20509997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients].
    Jung HW; Choi MS; Kim KH; Park SH; Yeon KK; Lee JH; Koh KC; Paik SW; Yoo BC
    Korean J Hepatol; 2009 Mar; 15(1):52-8. PubMed ID: 19346785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir.
    Sheen E; Trinh HN; Nguyen TT; Do ST; Tran P; Nguyen HA; Nguyen KK; Garcia RT; Nguyen MH
    Aliment Pharmacol Ther; 2011 Oct; 34(7):767-74. PubMed ID: 21806648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
    Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
    Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
    Kwak MS; Choi JW; Lee JS; Kim KA; Suh JH; Cho YS; Won SY; Park BK; Lee CK
    J Viral Hepat; 2011 Oct; 18(10):e432-8. PubMed ID: 21914060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
    Salpini R; Alteri C; Cento V; Pollicita M; Micheli V; Gubertini G; De Sanctis GM; Visca M; Romano S; Sarrecchia C; Andreoni M; Angelico M; Parruti G; Svicher V; Perno CF
    J Med Virol; 2013 Jun; 85(6):996-1004. PubMed ID: 23588725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.